In fact, a recently published phase I trial of decitabine with carboplatin in ovary cancer patients showed DNA hypomethylating activity with a decitabine-based regimen.[39] Several other clinical trials employing a similar strategy of hypomethylation or other epigenetic modulation to re-express ‘silenced’ hormone receptors or tumor suppressor genes in breast carcinomas are underway. The gene discussed is NR4A1; the disease is breast carcinoma.